Tyneside pharma firm Shield Therapeutics seeks to raise $10m through subscription by largest investor
Pharma company Shield Therapeutics has announced a subscription by its largest investor to raise $10m.
The company’s main product, which treats iron deficiency anaemia, was first launched in Europe under the Ferracru brand in 2019 but is now available in the US and other countries as Accrufer. The Newcastle company has signed an agreement with AOP Health International Management AG, in which the major shareholder has conditionally agreed to subscribe for 256,410,256 new ordinary shares.
The agreement is part of a broader funding move, which sees the firm launch a conditional offer for its existing retail shareholders to purchase new ordinary shares, aiming to raise up to £1m. AOP’s subscription is subject t
Recommend
Reusable mask maker that supplies NHS secures £1.6m
2025-03-22 11:20:27
2025-03-22 11:20:27
North Somerset robotics firm to expand Portishead base after securing £500k
2025-03-22 11:20:27
2025-03-22 11:20:27
'Success isn't hidden formula', says pension app founder after raising £1.8m
2025-03-22 11:20:27
2025-03-22 11:20:27
Stanlow refinery owner EET Fuels seals $650m funding deals – as reports suggest Hynet cluster could get billions of pounds in Government backing
2025-03-22 11:20:27
2025-03-22 11:20:27
Treasury minister defends pay packet of new value-for-money chief
2025-03-22 11:20:27
2025-03-22 11:20:27
Virgin Money's takeover by Nationwide building society is completed
2025-03-22 11:20:27
2025-03-22 11:20:27
Channel 4 invites black British entrepreneurs to apply for TV ad scheme worth £150k
2025-03-22 11:20:27
2025-03-22 11:20:27
Manchester’s Gaia Learning secures £550k venture capital funding
2025-03-22 11:20:27
2025-03-22 11:20:27
Leeds' Utc Travel receives £275k investment to grow online offer and create jobs
2025-03-22 11:20:27
2025-03-22 11:20:27
The Budget: 'Raising tax on businesses could hinder UK growth'
2025-03-22 11:20:27
2025-03-22 11:20:27
